J. Goldman & Co’s Terns Pharmaceuticals TERN Stock Holding History

J. Goldman & Co’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.26M	Sell	80,725 -122,467	-60%	-$5.03M	0.12%	213
2025 Q4	$8.21M	Buy	+203,192	New	+$4.7M	0.22%	128
2025 Q2	–	Sell	-67,500	Closed	-$186K	–	638
2025 Q1	$186K	Sell	67,500 -168,331	-71%	-$687K	﹤0.01%	436
2024 Q4	$1.31M	Buy	235,831 +31,890	+16%	+$216K	0.03%	303
2024 Q3	$1.7M	Buy	+203,941	New	+$1.68M	0.05%	243

Other funds holding TERN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

J. Goldman & Co's TERN Position: Q1 2026 in Review

J. Goldman & Co reduced its Terns Pharmaceuticals (TERN) stake by 60% in Q1 2026, selling an estimated $5.03M and leaving 80,725 shares worth $4.26M. The position accounts for 0.12% of the portfolio, ranked #213.

J. Goldman & Co first reported a position in TERN in Q3 2024 and has held it in 5 quarters since. The position peaked at $8.21M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

J. Goldman & Co held 80,725 shares of Terns Pharmaceuticals worth $4.26M as of Q1 2026.
J. Goldman & Co sold 122,467 Terns Pharmaceuticals shares in Q1 2026, an estimated $5.03M.
Terns Pharmaceuticals made up 0.12% of J. Goldman & Co's portfolio in Q1 2026, its #213 holding.
J. Goldman & Co first reported a position in Terns Pharmaceuticals in Q3 2024 and has held it in 5 quarters since.
J. Goldman & Co's Terns Pharmaceuticals position peaked at $8.21M in Q4 2025.
317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.